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UFH with vitamin K antagonist (VKA, e.g. warfarin),
LMWH with VKA, and UFH with LMWH and VKA.
Admissions using the three most common treatments
were compared with respect to length of stay (LOS), med-
ication costs and hospitalization costs. RESULTS: A total
of 953 primary DVT and 3933 primary PE admissions
were identiﬁed. Demographics were comparable for DVT
and PE patients. Most encounters involved treatment
with UFH/VKA (64%), followed by UFH/LMWH/VKA
(14%), and LMWH/VKA (13%). Median (interquartile
range) LOS for DVT patients treated with UFH/VKA,
UFH/LMWH/VKA, and LMWH/VKA were 5 (4–7), 5
(3–7), and 4 (2–6) days, respectively (p < 0.0001); corre-
sponding ﬁgures for PE patients were 6 (5–8), 6 (4–8),
and 5 (3–7) days, respectively (p < 0.0001). Median
(interquartile range) total hospitalization costs for 
DVT admissions were $3059 ($2251–$4306), $3515
($2106–$5351), $2587 ($1776–$3827) respectively (p <
0.0002). Corresponding costs for PE admissions were
$5152 ($3888–$7015), $5668 ($4077–$7928), $4537
($3144–$6168), respectively (p < 0.0001). UFH/LMWH/
VKA treatment was associated with the highest total drug
cost, while UFH/VKA treatment was associated with
lower anticoagulant and total medication costs. Higher
medication costs in the LMWH/VKA group were more
than offset by lower costs in other areas (shorter LOS)
yielding lower overall hospitalization costs. CONCLU-
SIONS: UFH/VKA was the most commonly employed
treatment, and was associated with lower medication
costs as compared to LMWH/VKA. However, LMWH/
VKA treatment was associated with reduced LOS and
lower overall hospitalization costs.
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OBJECTIVES: To compare health service utilization,
costs and outcomes of patients who used dihydropyridine
(DHP) and non-DHP calcium channel blockers (CCB) for
hypertension. METHODS: Utilizing pharmacy, member-
ship and medical data from a large managed care health
plan of over 2 million commercial members, this study
included continuously enrolled patients who had at least
2 or more CCB claims (DHP or non-DHP) between Juny
2000 and June 2001 and did not have a CCB claim 6
months prior to the index claim. Patients were followed
for 12 months after the index prescription and those who
had drug coverage for at least 60% of the days during
the follow-up period were included in the study. Geocod-
ing using national census data was performed to extract
socioeconomic data. Propensity-score matching of DHP
and non-DHP group was performed to adjust for selec-
tion bias. Overall and hypertension-related pharmacy and
medical service utilization and costs, and prevalence of
new renal and vascular-related diagnoses during follow-
up were determined for each study group. RESULTS: A
total of 4443 pairs of propensity-score matched patients
were included in the DHP and non-DHP study group.
Prevalence of new diagnosis for ischemic cerebrovascular
disease was lower in the non-DHP group than in the DHP
group (1.8% vs 2.5%; p < 0.05). Statistically signiﬁcant
difference in prevalence of new diagnosis for renal insuf-
ﬁciency, kidney dialysis, or proteinuria was not observed.
Average hypertension-related pharmacy and medical
costs were signiﬁcantly lower in the non-DHP group
($168 and $260) than in the DHP group ($184 and $370;
p < 0.05). The inter-group difference in costs was larger
among patients who used angiotensin converting enzyme
inhibitors (ACEI) concurrently with CCB. CONCLU-
SION: Treatment of hypertension with non-DHP CCB is
associated with lower prevalence of ischemic cerebrovas-
cular disease and lower pharmacy and medical costs as
compared to DHP CCBs, especially when used concur-
rently with ACEI.
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OBJECTIVE: The LIFE Study demonstrated a signiﬁcant
reduction in cardiovascular morbidity and mortality in
hypertensive patients with ECG left ventricular hyper-
trophy treated with losartan (versus treatment with
atenolol) over a mean period of 4.8 years. This reduction
was essentially related to a signiﬁcant 25% decrease (p =
0.001) in the risk of fatal and non-fatal stroke. The objec-
tive of this study was to compare the treatment costs
relating to each therapeutic strategy throughout the dura-
tion of the LIFE Study. METHODS: Data on efﬁcacy and
resources consumed were extracted from the published
results of the LIFE study. A cost minimization study was
carried out and the costs were calculated from the point
of view of the French healthcare system. The total esti-
mated direct costs included those relating to the medici-
nal product and management of the cardiovascular events
(myocardial infarction, angina pectoris, heart failure,
stroke and revascularization). The medicinal products
were valued on the basis of the purchasing price (retail
price inc. VAT), and hospitalization costs were estimated
on the basis of PMSI data and the national cost scale.
Indirect costs were not considered. RESULTS: Over the
4.8 years, the mean cost of losartan per patient ranged
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from €1132 (lower bound) to €1199 (upper bound). The
mean cost of atenolol per patient was €366. The mean
costs of the cardiovascular events were respectively €1969
and €2261 for losartan and atenolol groups. Therefore,
the total mean cost per patient ranged from €3101 to
€3169 for the losartan group and was estimated €2627
for the atenolol group. CONCLUSION: The annual
incremental cost for each patient treated with losartan
ranged from €99 to €113. This additional cost is associ-
ated with a signiﬁcant reduction in cardiovascular mor-
bidity and mortality (especially stroke).
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OBJECTIVE: To determine differences in costs in hyper-
tensive, NSAID-treated patients whose hypertension is
controlled or uncontrolled. METHODS: Claims data
from Careﬁrst BCBS were used to compare the mean
annualized total costs between groups. Patients were
included if they had a medical claim for hypertension
(ICD-9 of 401.xx-404.xx) between February 1, 1999 and
July 31, 2001 and the ﬁrst claim for an NSAID (index
date) between August 1, 1999 and July 31, 2001. NSAID
usage included non-speciﬁc NSAIDs and COX-2 speciﬁc
inhibitors. Uncontrolled hypertension was deﬁned as one
of the following occurring within 6 weeks following the
index date: 1) 1 hypertension related hospitalizations,
emergency room visit or outpatient visit or 2) a switch to
or addition of another antihypertensive drug. All billed
charges between the index date and end of the study
period were used to calculate mean annualized health care
costs. A logistic model was used to assess the determi-
nants of hypertension control. RESULTS: A total of 9805
patients were included. The difference in unadjusted
annualized mean total cost for controlled ($6774; N =
7282) and uncontrolled patients ($9342; N = 2523) was
$2568 (p < 0.0001). Mean annualized costs were $4856
(pre-index) and $4732 (post-index) for the controlled
group and $5038 (pre-index) and $5394 (post-index) for
the uncontrolled group (signiﬁcant at p < 0.001). Differ-
ences were consistently greater for hypertension related
than non-hypertension related costs. Patients were 1%,
and 28% less likely to be controlled, per year of increase
in age or they had diabetes, respectively. CONCLUSION:
Patients using an NSAID, with uncontrolled hypertension
incur incremental medical costs of approximately $2500
annually when compared to those with controlled hyper-
tension. Older or diabetic patients are more likely to have
uncontrolled hypertension. Further research is recom-
mended at the drug level, to determine if particular
NSAIDS, including COX-2 speciﬁc inhibitors, are associ-
ated with a greater likelihood of uncontrolled hyperten-
sion and if differences in total treatment costs exist by
drug.
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OBJECTIVES: The Joint National Committee for the Pre-
vention, Detection and Treatment of High Blood Pressure
(JNC-VI) has published guidelines recommending thi-
azide diuretics (TZDs) or beta-blockers for the initial
medication management of hypertension. Recent studies
have corroborated these guidelines by demonstrating no
difference in morbidity and mortality between chlorthali-
done, amlodapine, and lisinopril in the treatment of
hypertension. Thus, selection between these agents repre-
sents an issue of cost with similar outcomes. Hamilton
and Clause have reported the prevalence of these agents
for the treatment of hypertension in a sample of NYS
Medicaid recipients, and observed variances from 
treatment guidelines. Using their results and the NYS
Medicaid prescription database, differences in costs for
single-agent treatments were assessed. METHODS: Pre-
scription utilization data were abstracted from the NYS
Medicaid claims database for a sample of 2689 beneﬁ-
ciaries with hypertension in 1999. Three groups were
identiﬁed: a) 267 receiving only a TZD; b) 964 receiving
only a calcium antagonist (CA); and c) 941 receiving
either an ACEI or an ARB. Medicaid costs and days
supply were queried for the following drug classes: a)
ACEI; b) ARB; c) CA; and d) TZDs. Average cost-per-day
were calculated for each category. Results were then
adjusted for previously observed variances from treat-
ment guidelines. RESULTS: Cost/day for each group were
as follows: a) $0.18/day for TZDs; b) $1.58/day for CA;
and c) $1.18/day for ACEI or ARBs. Compared to TZD,
the excess costs for inappropriate CA therapy were esti-
mated at $1.40/day or $511 per patient per year. Total
potential patients beneﬁting from appropriate therapy
were estimated from national trends. With 328,578
hypertensive NYS Medicaid patients, inappropriate ther-
apies could account for more than $4.2 million in excess
expenditures. CONCLUSION: There is potential for 
signiﬁcant annual savings to NYS Medicaid through
improved application of JNC-VI guidelines to the initial
treatment of hypertension.
